Abstract 1596P
Background
Palliative care has shown a positive economic impact in oncology. However, research on its financial viability in oncology, especially in developing countries, is lacking. This study estimates hospitalization costs for cancer patients in the southeast region of Brazil.
Methods
We used a retrospective analysis of electronic medical records for cancer patients treated at a Cancer Center in the southeast region of Brazil. Inclusion criteria were adult patients with any type of cancer who had died at a hospital setting between January 2022 and March 2023. Patients were divided into two groups: those who received outpatient palliative care (OPCT) and those who did not receive any OPCT. Based on the available clinical outcomes of the sample, data was collected on the hospital admission date, length of stay until death, and the type of accommodation until death [admission at intensive care unit (ICU) versus general ward]. To estimate the costs, we used real-world data from private hospitals in the southeast region, measuring the general amounts spent on daily hospitalization and ICU stays, and their respective lengths of stay, without reference to any specific patient or procedures. We performed univariate comparisons using Linear Regression.
Results
Out of the 72 patients with cancer, 29 were followed by the OPCT team, while 43 were not. The average cost of hospitalization for patients who did not receive the OPCT was found to be R$ 20,000.00 (€ 3,651.00; SD = 9.19) higher than those who received OPCT (p = 0.03). We observed that patients who were admitted to the ICU had hospitalization cost, on average, R$ 17,800.00 (€ 3,249.00; SD = 9.61) more than those who stayed in general ward (p = 0.06).
Conclusions
Our study highlights the economic benefits of providing OPCT in a developing country. Based on this analysis, OPCT can reduce healthcare costs by decreasing the length of hospital stay and preventing unnecessary ICU admissions. Our study suggest that policymakers and healthcare providers should prioritize the provision of OPCT in Brazil, and this type of support should be considered as an essential component of end-of-life care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Oncoclinicas.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05